New Obesity Target Structural Analysis Service
InquiryThe global landscape of metabolic disease is shifting rapidly. As obesity is increasingly recognized as a complex, multi-factorial chronic disease rather than a simple caloric imbalance, the demand for next-generation therapeutics has surged beyond traditional GLP-1 receptor agonists. Recent clinical and epidemiological data highlight the urgent need for treatments that address diverse pathophysiology, including adipocyte reprogramming, energy expenditure modulation, and the mitigation of metabolic dysfunction-associated steatotic liver disease (MASLD/MASH).
Structural Analysis Services for Novel Obesity Targets
At Protheragen, we provide specialized new obesity target structural analysis services designed to bridge the gap between genomic discovery and hit optimization. We focus exclusively on the preclinical stage, offering the high-resolution structural insights necessary to design small molecules, peptides, and biologics against emerging targets such as GIPR, GCCR, amylin receptors, and novel mitochondrial uncouplers. Our mission is to provide the structural blueprint that enables your drug discovery team to overcome "undruggable" challenges in the metabolic space.
Core Technologies
Protheragen leverages a suite of high-end biophysical and structural biology platforms tailored for the unique challenges of metabolic membrane proteins and complex signaling complexes.
Ideal for visualizing large GPCR-G protein signaling complexes and transient intermediate states of obesity-related receptors.
Utilizing high-intensity synchrotron radiation to resolve atomic-level details of small molecule binding pockets and protein-protein interfaces.
Enabling structural determination from sub-micron-sized crystals, accelerating timelines for targets that are difficult to crystallize at scale.
Providing dynamic structural information on conformational changes and binding kinetics to complement static atomic models.
Solution Scope
Protheragen offers an exhaustive range of structural analysis services focused on the frontiers of obesity and metabolic research. Our preclinical expertise covers:
- Incretin and Beyond
Comprehensive structural mapping of GLP-1R, GIPR, and Glucagon Receptor (GCGR) co-complexes, including dual and triple agonist binding modes.
- Adipocyte Reprogramming Targets
Structural characterization of proteins involved in white-to-brown fat thermogenesis and lipid droplet regulation.
- Central Nervous System (CNS) Regulators
High-resolution analysis of melanocortin-4 receptor (MC4R) and other hypothalamic signaling pathways governing satiety and energy intake.
- MASH/MASLD Related Targets
Atomic-level studies of targets at the intersection of obesity and liver pathology, including FXR and THR-β modulators.
- Fragment-Based Lead Discovery (FBLD) Support
Structural screening of fragment libraries against novel metabolic targets to identify unique allosteric pockets.
- Antibody-Antigen Epitope Mapping
Precise determination of binding interfaces for therapeutic antibodies targeting metabolic cell-surface markers.
Contact Our Team to Discuss Your Specific Target
Workflow
Our streamlined workflow ensures that your project moves from target sequence to high-resolution structure with maximum efficiency and transparency.
Fields of Application
The structural insights generated by Protheragen are critical for various stages of preclinical drug development:
- Rational Drug Design: Transitioning from high-throughput screening hits to optimized leads with improved potency and selectivity.
- Selectivity Profiling: Analyzing structural differences between receptor subtypes to minimize off-target effects and improve safety profiles.
- Species Cross-Reactivity: Comparing human and ortholog structures to validate preclinical animal models.
- Formulation Development: Understanding the structural stability of biologics to optimize delivery and shelf-life.
Advantages
Partnering with Protheragen provides your pipeline with a competitive edge through deep technical expertise and validated methodologies.
Precision in "Undruggable" Spaces
We specialize in membrane proteins and unstable complexes that standard platforms often fail to resolve.
Metabolic Expertise
Our scientists understand the nuances of obesity biology, ensuring that the structural data we provide is biologically relevant to the disease state.
Accelerated Timelines
By integrating MicroED and high-throughput Cryo-EM screening, we significantly reduce the time from target validation to lead optimization.
IP Protection & Data Security
We maintain the highest standards of confidentiality, ensuring your novel targets and structural data remain your exclusive intellectual property.
Contact our specialists today to accelerate your hit-to-lead phase.
Customer Review
Breakthrough Insights for Dual-Agonist Optimization
"The structural data provided by Protheragen was a turning point for our dual-agonist program. We had struggled for over a year to understand why our leads weren't showing the expected selectivity. The Cryo-EM structure Protheragen delivered revealed a subtle conformational shift in the extracellular loop that we hadn't accounted for. This insight allowed us to redesign the scaffold, resulting in a 10-fold increase in potency. We look forward to continuing our partnership on our upcoming MASH targets."
Dr. S. B., Senior Director of Discovery Biology
Unparalleled Technical Expertise in Stabilizing Fragile Complexes
"Protheragen operates as a true extension of our internal team. Their expertise in stabilizing fragile metabolic complexes is unparalleled. The MicroED results they generated for our small molecule program provided atomic-level clarity that was previously impossible to obtain. Their commitment to quality and transparent communication makes them our preferred partner for structural biology."
Dr. V. Z., Head of Early-Stage Pipeline
Frequently Asked Questions
-
Does Protheragen provide clinical trial support?
No, we focus exclusively on preclinical structural biology and biophysical characterization to support early-stage drug discovery.
-
What resolution can I expect for a typical GPCR project?
While resolution depends on the target, we routinely achieve 2.5Å to 3.2Å for membrane protein complexes using our optimized Cryo-EM workflows.
-
Can you handle membrane proteins that are difficult to express?
Yes, we utilize specialized detergent screening and nanodisc reconstitution techniques to stabilize even the most challenging targets.
-
Do you provide assistance with ligand design?
We provide the structural data and computational analysis that inform design; however, the actual chemical synthesis is typically handled by the client or a medicinal chemistry partner.
-
How much sample is required for a structural study?
One of our strengths is the ability to work with low-microgram quantities, especially when using MicroED or Cryo-EM.
-
Can you resolve allosteric binding sites?
Absolutely. Our structural analysis is specifically geared toward identifying novel pockets outside the orthosteric site.
-
What is the typical turnaround time for a de novo structure?
Depending on the target complexity, timelines generally range from 3 to 6 months from protein production to final model.
-
Is the data provided compatible with standard molecular modeling software?
Yes, we provide PDB/CIF files along with raw maps and comprehensive validation reports compatible with all major platforms.
-
Do you offer biophysical validation alongside structural data?
Yes, we recommend using SPR or MST (microscale thermophoresis) to correlate structural findings with binding affinity.
Contact Us
Protheragen is dedicated to empowering the next generation of obesity therapeutics through precision structural biology. Whether you are targeting established pathways or exploring novel metabolic checkpoints, our team provides the technical excellence required to move your project forward with confidence. Welcome to Contact Protheragen and start communication.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.